Clinical Trials

Sponsor: MUSC

Sponsor Study ID: 103408

Study Title: A Phase 1B Trial of Tarloxotinib and Sotorasib in Patients with KRAS G12C Mutations

Phase: I/II

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Lung

Study Objectives: Primary Objectives: To evaluate the RP2D, safety, and tolerability of tarloxotinib in combination with sotorasib in patients with KRAS G12C mutated advanced non-small cell lung cancer (NSCLC). To evaluate the tumor objective response rate (ORR) assessed by RECIST 1.1 criteria of the combination of tarloxotinib with sotorasib. Secondary Objectives To evaluate other measures of efficacy of the combination of tarloxotinib with sotorasib in patient with KRAS G12C mutated advanced NSCLC

For more information about the trial above please contact the study team:

Principal Investigator, Mariam Alexander, at alexanma@musc.edu.
Study Coordinator, Alexandra Leitner, at leitnera@musc.edu, or please call +1 843-792-1507.

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)